Reaching Others

<<  Previous Page

 

Dr. Gene D. Morse
Pharmacy Practice

Professor, School of Pharmacy and Pharmaceutical Sciences

Associate Director, NYS Center of Excellence in Bioinformatics

and Life Sciences

University at Buffalo

701 Ellicott Street

Buffalo, NY 14203

Phone: (716) 881-7464

Fax: (716) 849-6890


Email: emorse@buffalo.edu

 

No Photograph
 Research Overview

 

Gene D. Morse, Pharm.D., FCCP, BCPS, is professor and associate director of the New York State Center of Excellence in Bioinformatics and Life Sciences at the University at Buffalo (UB), State University of New York. Dr. Morse has been actively involved in HIV clinical pharmacology research since the introduction of antiretrovirals in 1986. Dr. Morse is the director of the Translational Pharmacology Research Core, a collaboration between the other research cores in the NYS Center of Excellence in Bioinformatics and Life Sciences, the School of Pharmacy and Pharmaceutical Sciences and other units within the Academic Health Center and the Buffalo Niagara Medical Campus. The TPRC has four primary components: 1) Core Laboratory Facility for Bioanalysis and Drug Development; 2) Healthcare Informatics and Medication Management Research Network (MMRN); 3) Translational Pharmacogenomics and Nanomedicine Program; and 4) International Pharmacotherapy Education Initiative.

 

Dr. Morse has National Institute of Allergy and Infectious Diseases (NIAID) support for the UB AIDS Clinical Trials Group (ACTG) Pharmacology Specialty Laboratory and a contract for the HIV Clinical Pharmacology Quality Assurance Program. These programs integrate with the NIH Fogarty International Center AIDS International Training and Research Program, which Dr. Morse directs with the University of Zimbabwe. Dr. Morse directs the Adherence Pharmacology Unit and HIV Treatment Education Program at the Erie County Medical Center in Buffalo, NY. Dr. Morse also directs the UB HIV Clinical Pharmacology Laboratory, which has gained an international reputation for its work in bioanalysis, pharmacokinetics, and pharmacogenomics. In addition, Dr. Morse is director of the Medication Management Research Network, a federally certified patient safety organization and a network for health information technology research. Dr. Morse holds leadership positions within the UB Clinical and Translational Research Consortium and the University of Rochester Clinical and Translational Sciences Institute. Dr. Morse has > 25 years of NIH, industry and philanthropic research support with extensive experience in grant applications and mentoring. Dr. Morse has mentored over 90 students from the graduate, post-graduate, and post-doctoral levels.

 

Limited Faculty Profile

 

Brief Statement of Experience

 

Contributed to national international research programs in HIV Clinical Pharmacology and established a core analytical laboratory and clinical program to facilitate translational research.

 

Awards and Honors

 

Volwiler Research Achievement Award, American Association of Colleges of Pharmacy. (July 2012)

Award for Outstanding Contributions to International Education, UB Council on International Studies and Programs (CISP), June 2010

 

 

RESEARCH

 

Published Intellectual Contributions (~160 publications)

Manuscripts ( from 2010 – October 2013 only listed below)

  1. Baker J, Rainey PM, Moody DE, Morse GD, Ma Q, McCance-Katz EF. Interactions between Buprenorphine and Antiretrovirals: Nucleos(t)ide Reverse Transcriptase Inhibitors (NRTI) Didanosine, Lamivudine, and Tenofovir. Am J Addict. 2010 Jan 1;19(1):17-29. PMCID: PMC3723405
  2. McCance-Katz EF, Moody DE, Morse GD, Ma Q, Rainey PM. Lack of Clinically Significant Drug Interactions between Nevirapine and Buprenorphine. Am J Addict. 2010 Jan 1; 19(1):30-7. PMCID: PMC3723410.
  3. Bruce RD, Altice FL, Moody DE, Morse GD, Andrews L, Lin SN, Fang WB, Ma Q, Friedland GH. Pharmacokinetic Interactions Between Buprenorphine/Naloxone and Once-Daily Lopinavir/Ritonavir. J Acquir Immune Defic Syndr 2010 Aug 15; 54(5): 511-4. PMID: 20672450
  4. DiFrancesco R, Rosenkranz SL, Mukherjee AL, Demeter LM, Hongyu J, DiCenzo R, Dykes C, Rinehart A, Albrecht M, Morse GD. Quality Assessment for Therapeutic Drug Monitoring in AIDS Clinical Trials Group (ACTG 5146): A Multicenter Clinical Trial. Ther Drug Monit. 2010 Aug; 19(1): 30-7.  PMCID: PMC2936454
  5. Ribaudo HJ, Liu H, Schwab M, Schaeffeler E, Fichelbaum M, Motsinger-Reif A, Ritchie MD, Zanger UM, Acosta EP, Morse GD, Gulick RM, Robbins GK, Clifford D, Haas DW.  Effect of CYP2B6, ABCB1, and CYP3A5 Polymorphisms on Efavirenz Pharmacokinetics and Treatment Response: An AIDS Clinical Trials Group Study. J Infect Dis. 2010 Sep 1; 202(5):717-22. PMCID: PMC2919241
  6. Crutchley RD, Ma Q, Sulaiman A, Hochreiter J, Morse GD. Within Patient Atazanavir Trough Concentration Monitoring in HIV-1 Infected Patients. J Pharm Prac. 2010 November 22; DOI: 10.1177/0897190010380923 PMID: 21712217
  7. Hammer SM, Ribaudo H, Bassett R, Mellors JW, Demeter LM, Coombs RW, Currier J, Morse GD, Gerber JG, Martinez AI, Spreen W, Fischl MA, Squires KE. A Randomized, Placebo-Controlled Trial of Abacavir Intensification in HIV-1-Infected Adults With Virologic Suppression on a Protease Inhibitor-Containing Regimen. HIV Clin Trials. 2010 Nov-Dec; 11(6):312-24. PMCID: PMC3108099
  8. Fehintola FA, Akinyinka OO, Adewole IF, Maponga CC, Ma Q, Morse GD. Drug Interactions in the Treatment and Chemoprophylaxis of Malaria in HIV Infected Individuals in Sub Saharan Africa. Curr Drug Metab. 2011Jan; 12(1):51-56. PMCID:PMC3233991
  9. Bepe N, Madanhi N, Mudzviti T, Gavi S, Maponga CC, Morse GD. The Impact of Herbal Remedies on Adverse Effects and Quality of Life in HIV-Infected Individuals on Antiretroviral Therapy. J Infectious Dis. 2011Feb; 5(1):48-53. PMCID:PMC3424263
  10. Daar ES, Tierney C, Fischl MA, Sax PE, Mollan K, Budhathoki C, Godfrey C, Jahed NC, Myers L, Katzenstein D, Farajallah A, Rooney JF, Pappa KA, Woodward WC, Patterson K, Bolivar H, Benson CA, Collier AC, (Morse GD) AIDS Clinical Trials Group Study A5202 Team. Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1.  Ann Intern Med. 2011 Apr 5; 154(7): 445-56. PMCID: PMC3430716
  11. Ma Q, Zingman BS, Luque A, Fischl MA, Gripshover B, Venuto C, DiFrancesco R, Forrest A, Morse GD.  Therapeutic Drug Monitoring of Protease Inhibitors and Efavirenz in HIV-Infected Individuals with Active Substance Related Disorders. Ther Drug Monit. 2011 Jun; 33(3): 309-314.  PMCID: PMC3120966
  12. Albrecht M, Mukherjee AL, Tierney C, Morse GD, Dykes C, Klingman KL, Demeter LM. A Randomized Clinical Trial Evaluating Therapeutic Drug Monitoring (TDM) for Protease Inhibitor-based Regimens in Antiretroviral -Experienced HIV-infected Individuals: Week 48 Results of the A5146 Study. HIV Clin Trials. 2011 Jul-Aug;12(4):201-14.  PMCID: PMC3328407
  13. Sax PE, Tierney C, Collier AC, Daar ES, Mollan K, Budhathoki C, Godfrey C, Jahed NC, Myers L, Katzenstein D, Farajallah A, Rooney JF, Ha B, Woodward WC, Feinberg J, Tashima K, Murphy RL, Fischl MA, (Morse GD) AIDS Clinical Trials Group Study A5202 Team. Abacavir/lamivudine versus Tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results.  J Infect Dis. 2011 Oct 15;204(8):1191-201. PMCID: PMC3173503
  14. Nanzigu S, Eriksen J, Makumbi F, Lanke S, Mahindi M, Kiguba R, Beck O, Ma Q, Morse GD, Gustafsson LL, Waako P. Pharmacokinetics of the nonnucleoside reverse transcriptase inhibitor efavirenz amon HIV-infected Ugandans.  HIV Med.2011 Nov; DOI: 10.1111/j.1468-1293.2011.00952.x. PMID: 22107359
  15. Oramasionwu CU, Hunter JM, Brown CM, Morse GD, Lawson KA, Koeller JM, Frei CR. Cardiovascular disease in Blacks with HIV/AIDS in the United States: A Systematic Review of the Literature. Open AIDS J.  2012; 6, 29-35. Epub 2012 Apr 26. PMCID: PMC3343316
  16. Gruber VA, Rainey PM, Moody DE, Morse GD, Ma Q, Prathikanti S, Pade PA, Alvanzo AA, McCance-Katz EF.  Interactions between buprenorphine and the protease inhibitors darunavir-ritonavir and fosamprenavir-ritonavir.  Clin Infect Dis.  2012 Feb 54(3): 414-23.  PMCID:PMC3258270
  17. Mudzviti T, Maponga CC, Khoza S, Ma Q, Morse GD.  The impact of herbal drug use on adverse drug reaction profiles of patients on antiretroviral therapy in zimbabwe.  AIDS Res Treat. 2012; 2012 434171. Epub 2012 Mar 19.  PMCID: PMC3313558
  18. Fehintola FA, Scarsi KK, Ma Q, Parikh S, Morse GD, Taiwo B, Akinola IT, Adewole IF, Lindegardh N, Phakderaj A, Ojengbede O, Murphy RL, Akinyinka OO, Aweeka FT.  Nevirapine-Based Antiretroviral Therapy Impacts Artesunate and Dihydroartemisinin Disposition in HIV-Infected Nigerian Adults.  AIDS Res Treat. 2012; 2012: 703604.  Epub 2012 Mar 5.  PMCID: PMC3303559
  19. Hochreiter J, McCance-Katz EF, Lapham J, Ma Q, Morse GD.  Disulfram Metabolite S-Methyl-N, N-Diethylthiocarbamate Quantitation in Human Plasma With Reverse Phase Ultra Performance Liquid Chromatography and Mass Spectrometry.  J Chromatogr B Analyt Technol Biomed Life Sci. 2012 May 15; 897:80-4. PMCID: PMC3348964
  20. Yanes PK, Morse GD, Hsiao CB, Simms L, Robert JE. Autobiographical Memory Specificity and the Persistence of Depression in HIV-Positive Patients: Rumination and Social Problem Solving Skills as Mediators. Cogn Emot.  2012 June 7. [Epub ahead of print] PMID: 22671904
  21. Morse GD, Maartens G, Maponga CC, Ma Q.  Global HIV/AIDS Clinical and Translational Pharmacology.  AIDS Res Treat.  2012;2012:973627. Epub 2012 Jul 18.  PMCID: PMC3407604
  22. Hochreiter J, Lapham J, Wong-Staal F, McKelvey J, Sulkowski M, Glesby M, Johnson V, Morse GD.  ITX5061 Quantitation in Human Plasma with Reverse Phase Liquid Chromatography and Mass Spectrometry Detection. Antivir Ther. 2012 Sep 6. [Epub ahead of print]. 18(3):329-36.  PMID: 22954720
  23. Oramasionwu CU, Morse GD, Lawson KA, Brown CM, Koeller JM, Frei CR.  Hospitalizations for Cardiovascular Disease in African-Americans and Whites with HIV/AIDS. Population Health Management.  2012 Nov 29. PMID: 23194035
  24. Mudzviti T, Sibanda M, Gavi S, Maponga CC, Morse GD. Implementing a pharmacovigilance program to evaluate cutaneous adverse drug reactions in an antiretroviral access program.  J Infect Dev Ctries. 2012 Nov 26;6(11):806-8. doi: 10.3855/jidc.1908. PMCID: PMC3535441
  25. Holzinger ER, Grady B, Ritchie MD, Ribaudo HJ, Acosta EP, Morse GD, Gulick RM, Robbins GK, Clifford DB, Daar ES, McLaren P, Haas DW. Genome-Wide Association Study of Plasma Efavirenz Pharmacokinetics in AIDS Clinical Trials Group Protocols Implicates Several CYP2B6 Variants.  Pharmacogenet and Genomics. 2012 Dec;22(12):858-867.. [Epub ahead of print] PMCID: PMC3614365
  26. Oramasionwu CU, Koeller JM, Lawson KA, Brown CM, Morse GD, Frei CR. The State of Disparities in Opportunistic Infection Prophylaxis for Blacks with HIV/AIDS. Med Care. 2012 Nov. 50(11):920-7.PMCID: PMC3470654
  27. Ribaudo HJ, Daar ES, Tierney C, Morse GD, Mollan K, Sax PE, Fischl MA, Collier AC, Haas DW. Impact of UGT1A1 Gilbert Variant on Discontinuation of Ritonavir-boosted Atazanavir in AIDS Clinical Trials Group Study A5202. J Infect Dis. 2013 Feb;207(3):420-425. [Epub 2012 Nov 12] PMCID: PMC3537445
  28. DiFrancesco R, Maduke G, Patel R, Taylor CR, Morse GD. Antiretroviral bioanalysis methods of tissues and body biofluids. Bioanalysis. 2013 Feb;5(3):351-68. doi: 10.4155/bio.12.319. PMID: 23394701
  29. Zhang X, Tierney C, Albrecht M, Demeter LM, Morse GD, DiFrancesco R, Dykes C, Jiang H, Haas DW.  Discordant Associations between SLCO1B1 21TàC and Plasma Levels of Ritonavir-boosted Protease Inhibitors in AIDS Clinical Trials Group Study A5146.Ther Drug Monit. 2013 Apr;35(2):209-16. doi: 10.1097/FTD.0b013e318280d0ad. PMCID: PMC3603284
  30. DiFrancesco R, Tooley K, Rosenkranz SL, Siminski S, Taylor CR, Pande P, Morse GD. Clinical Pharmacology Quality Assurance for HIV and Related Infectious Diseases Research. Clin Pharmacol Ther. 2013 Jun;93(6):479-82.  PMID: 23588323
  31. Mikula J, Sawyer JR, Ma Q, Sulaiman AS, Hsiao CB, Morse GD. Comparative effectiveness of darunavir 1,200 mg daily and approved dosing strategies for protease inhibitor-experienced patients. AIDS Res Treat. 2013 June. Vol. 2013, Article ID 687176, 4 pages. PMCID: PMC3730211
  32. Schifitto G, Ma Q, Gelbard HA, Maggirwar SB, Dewhurst S, Gendelman HE, Peterson DR, Difrancesco R, Hochreiter J, Morse GD.  CEP-1347 and Atazanavir Pharmacokinetics in HIV-infected Patients.  Clin Pharmacol Ther.  J Neurovirol. 2013 Jun;19(3):254-60. doi: 10.1007/s13365-013-0172-z. Epub 2013 Jun 5. PMCID: PMC3760277
  33. Sulkowski MS, Kang M, Matining R, Wyles D, Johnson V, Morse GD, Amorosa V, Bhattacharya D, Wong-Staal F, Glesby MJ, ACTG A5277 Protocol Team. Safety and Antiviral Activity of the HCV Entry Inhibitor ITX 5061 in Treatment-Naïve HCV- Infected Adults:  A Randomized, Double-Blind, Phase 1b Study. J Infect Dis. 2013 Sep 16. PMID: 24041792.
  34. DiFrancesco R, Rosenkranz SL, Taylor CR, Pande PG, Siminski SM, Jenny RW, Morse GD. Clinical Pharmacology Quality Assurance (CPQA) Program: Longitudinal Analysis of Antiretroviral (ARV) Proficiency Testing for International Laboratories. Ther Drug Monit. 2013 Oct;35(5):631-42. doi: 10.1097/FTD.0b013e31828f5088. PMCID: PMC3781596
  35. McCance-Katz EF, Gruber VA, Beatty G, Lum P, Ma Q, Difrancesco R, Hochreiter J, Wallace PK, Faiman MD, Morse GD.  Interaction of disulfiram with antiretroviral medications: Efavirenz increases while atazanavir decreases disulfiram effect on enzymes of alcohol metabolism. Am J Addict. 2013 Oct 11. doi: 10.1111/j.1521-0391.2013.12081.x. [Epub ahead of print] PMID: 24118434

 Conference Presentations

International (from 2010 – October 2013 only listed below)

  1. Mudzviti T, Sibanda M, Maponga C, Morse GD, Gavi S.  An Evaluation of Cutaneous Adverse Drug Reactions and Antiretroviral Therapy Use in HIV Infected Patients in a Resource Limited Setting (Abstract).  11th International Workshop on Clinical HIV Pharmacology of HIV Therapy, Sorrento, Italy, April, 2010.
  2. Maponga C, DiFrancesco R, Tooley KM, Jaravani P, Ma Q, Morse GD.  Establishing an AIDS International Training and Research Program (AITRP) to Increase Capacity for HIV Clinical Pharmacology Research in Southern African Countries.  18th International AIDS Conference (AIDS), Vienna, Austria, July, 2010.
  3. DiFrancesco R, Tooley KM, Pande P, Siminski S, Morse GD.  HIV Clinical Pharmacology Quality Assurance (CPQA) and Quality Control Program: Current Status and Planning for Expanded Research.  18th International AIDS Conference (AIDS 2010), Vienna, Austria, July, 2010.
  4. Hochreiter J, Lapham J, Wong-Staal F, McKelvy JF, Sulkowski M, Glesby M, Johnson VA, Morse GD.  Quantitation of ITX 5061, a Scavenger Receptor Class B, type I Antagonist in Human Plasma with LCMS.  International Conference on Viral Hepatitis (ICVH), Baltimore, MD, April, 2011.
  5. Nanzigu S, Eriksen J, Lanke S, Makumbi F, Mahindi M, Beck O, Ma Q, Morse GD, Gustafsson L, Waako P. Pharmacokinetics of NNRTI Efavirenz among HIV Infected Ugandans.  12th International Workshop on Clinical Pharmacology of HIV Therapy, Miami, FL, April, 2011.
  6. Liu H, Ribaudo HJ, Acosta EP, Morse GD, Daar ES, Robbins GK, Benson C, Haas DW, and the AIDS Clinical Trials Group (ACTG) (2011).  Pharmacogenetics of low plasma efavirenz (EFV) concentrations in AIDS Clinical Trials Group (ACTG) studies: Analysis NWCS 301.  12th International Workshop on Clinical Pharmacology of HIV Therapy, Miami, FL, April, 2011; Abstract P-22.
  7. DiFrancesco R, Taylor CR, Hochreiter JS, Maponga CC, Morse GD.  Global Strategy for Quality Assessment of Clinical Pharmacology Research Laboratories.  6th International AIDS Society (IAS) Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2011), Rome, Italy, July, 2011.
  8. Hamandawana TM, Bepe N, Dzangare J, Maponga CC, Morse GD.  Patient Perceptions, Knowledge, and Practices of the Role of Nutrition in HIV/AIDS Management in a Resource Limited Setting.  6th International AIDS Society (IAS) Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2011), Rome, Italy, July, 2011.
  9. DiFrancesco R, Tooley KM, Jenny RW, Parsons T, Rocci ML Jr., Morse GD.  Quality Assurance of Antiretroviral Assays in Human Biofluids and Tissues during HIV Prevention and Treatment Research.  6th International AIDS Society (IAS) Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2011), Rome, Italy, July, 2011.
  10. DiFrancesco R, Tooley KM, Taylor CR, Hochreiter JS, Maponga CC, Morse GD.  Quality Assurance Initiative for Clinical Pharmacology Laboratory Development in Resource Limited Countries.  6th International AIDS Society (IAS) Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2011), Rome, Italy, July, 2011.
  11. DiFrancesco R, Pande PG, Siminski SM, Morse GD.  Reproducibility of Antiretroviral Proficiency Testing.   6th International AIDS Society (IAS) Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2011), Rome, Italy, July, 2011.
  12. Jani ZT, Monera TG, Maponga CC, Morse GD.  An Assessment of the Variability of Labeling and Counseling Information of Selected Herbal Medications Marketed for HIV and AIDS in Harare, Zimbabwe. 6th International AIDS Society (IAS) Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2011), Rome, Italy, July, 2011.
  13. Bunu L, Monera TG, Maponga CC, Morse GD.  Prevalence of heterosexual anal intercourse and oral sex among high risk populations in Harare, Zimbabwe.  6th International AIDS Society (IAS) Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2011), Rome, Italy, July, 2011.
  14. Difrancesco R, Felton CM, Morse GD.  Anticipating Research Capacity for HCV Drug-Drug Interactions.  2nd International Conference on Viral Hepatitis (ICVH 2012).  New York, NY. March 26-27, 2012.
  15. Fehintola FA, Scarsi KK, Ma Q, Parikh S, Morse GD, Lindegardh N, Akinyinka OO, Aweeka FT.  Pharmacokinetics of Amodiaquine and Desethylamodiaqine in HIV-infected Patients with and without Nevirapine-Containing Antiretroviral Therapy.  13th International Workshop on Clinical Pharmacology of HIV Therapy, Barcelona, Spain, April 2012.
  16. Felton CM, Sayidine F, DiFrancesco R, Bednasz C, Lliguicota F, Morse GD.  Novel Mechanism for Rapid Pharmacokinetic Drug Interaction Data Evaluation for NIH Clinical Trials.  13th International Workshop on Clinical Pharmacology of HIV Therapy, Barcelona, Spain, April 2012. Podium Presentation
  17. Felton CM, Sayidine F, DiFrancesco R, Bednasz C, Lliguicota F, Morse GD.  Informatics-Based, Drug Interactions Database for Clinical Protocols.  XIX International AIDS Conference (AIDS/IAS 2012), Washington, D.C., July 2012.
  18. Venuto CS, Ma Q, Daar ES, Sax PE, Fischl MA, Collier AC, Mollan K, Smith KY, Tierney C, Morse GD, ACTG 5202 Protocol Team.  Tenofovir plasma pharmacokinetics in AIDS Clinical Trials Group Study A5202.  XIX International AIDS Conference (AIDS/IAS 2012), Washington, D.C., July 2012.
  19. Venuto CS, Mollan K, Ma Q, Daar ES, Sax PE, Fischl M, Collier A, Smith K, Lu D, Tierney C, Morse GD, ACTG 5202 Protocol Team.  Atazanavir Pharmacokinetics and Efficacy and Safety Outcomes by Sex in AIDS Clinical Trials Group Study 5202 (A5202).  XIX International AIDS Conference (AIDS/IAS 2012), Washington, D.C., July 2012.
  20. Difrancesco R, Rosenkranz SL, Taylor CR, Pande PG, Siminski SM, Jenny RM, Morse GD.  Clinical Pharmacology Quality Assurance (CPQA) Program: Longitudinal Analysis of Antiretroviral (ARV) Proficiency Testing for International Laboratories. XIX International AIDS Conference (AIDS/IAS 2012), Washington, D.C., July 2012.
  21. Johnson DH, Venuto C, Daar ES, Morse GD, Sax P, Fischl MA, Collier AC, McLaren P, Ritchie M, Haas DW. Genome-wide Association Study of Atazanavir (ATV) Pharmacokinetics (PK) and Indirect Hyperbilirubinemia (HBR). Conference on Retroviruses and Opportunistic Infections(CROI) , Atlanta, GA, March 2013.
  22. Sulkowski M, Kang M, Matining R, Wyles D, Johnson V, Morse GD, Amorosa V, Bhattacharya D, Wong-Staal F, Glesby M. A Randomized, Double-blind, Phase 1b Study of the HCV Entry Inhibitor ITX 5061 in Treatment-naive, HCV monoinfected Adults: ACTG A5277. Conference on Retroviruses and Opportunistic Infections(CROI), Atlanta, GA, March 2013.
  23. Maponga CC, DiFrancesco R, Tooley K, Kaufman FS, Prasad PN, Morse GD. Zimbabwe Capacity Building for HIV Implementation Research. Global Implementation Conference, Washington D.C., August 2013.

National (from 2010 – October 2013 only listed below)

  1. Felton C, Sayidine F, Wrobel M, Purdy C, Ellis D, Venuto R, Dombroski E, Gbadamosi F, Grieser J, Govindaraju V, Dandona P, Sanders E, Morales A, Seelman D, Hughes A, Lliguicota F, Manzella K, Ma Q, Bessette R, Morse GD. Pharmaceutical Safety Initiative: Enhancing Patient Safety with Information Technology and Biomedical Informatics. Pharmacy Safety Forum, Albany, NY, June, 2010.
  2. Tooley K, Morse GD. Pharmacology Study Conduct in IMPAACT Protocols. International Maternal, Pediatric, and Adolescent AIDS Clinical Trials Group Annual Meeting (IMPAACT), Washington. DC, June, 2010.
  3. DiFrancesco R, Morse GD. Pharmacology Study Conduct in ACTG Protocols. AIDS Clinical Trials Group (ACTG) Annual Meeting, Washington, DC, June, 2010.
  4. Ma Q, Brazeau D, Zingman B, Luque A, Fischl M, Gripshover B, DiFrancesco R, Forrest A, Morse GD. Interindividual Variability of ABCB1 Expression in Peripheral Blood Mononuclear Cells from HIV-Infected Patients. 2010 Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Boston, MA, September, 2010.
  5. Ribaudo HJ, Daar ES, Tierney C, McLaren PJ, Budhathoki C, Sax PE, Richardson DM, Morse GD, de Bakker PIW, Haas DW. Pharmacogenetics of Change in Calculated Creatinine Clearance with Regimens Containing Tenofovir Disoproxil Fumarate (TDF) in AIDS Clinical Trials Group (ACTG) Study A5202. 18th Conference on Retroviruses and Opportunistic Infections (CROI), Boston, MA, February, 2011; Abstract N-154.
  6. McLaren PJ, Ribaudo HJ, Daar ES, Robbins GK, Haubrich R, Acosta EP, Morse GD, de Bakker PIW, Haas DW (2011). Whole Genome Association Study (GWAS) of Virologic Failure with Efavirenz (EFV) and/or Abacavir (ABC)-Containing Regimens in AIDS Clinical Trials Group (ACTG) Studies. 18th Conference on Retroviruses and Opportunistic Infections (CROI), Boston, MA, February, 2011; Abstract N-153.
  7. Gavi S, Mudzviti T, Sayidine F, Ma Q, Tooley K, DiFrancesco R, Bessette RW, Morse GD, Maponga CC. Establishing an International Network for Using Health Information Technology in HIV/TB Medication Management Research. 2011 AMIA Summit on Clinical Research Informatics (CRI), San Francisco, CA, March, 2011.
  8. Oramasionwu C, Lawson K, Brown CM, Koeller J, Morse GD, Frei C. Use of Opportunistic Infection (OI) Prophylaxis between Blacks and Whites with HIV/AIDS. 2011 Infectious Diseases Society of America (IDSA), Boston, MA, October, 2011.
  9. Venuto CS, Ma Q, Mollan K, Tierney C, Lu D, Smith KY, Daar E, Sax P, Fischl MA, Collier AC, Morse GD and ACTG 5202 Protocol Team. Effect of Sex and NRTIs on Atazanavir Pharmacokinetics in AIDS Clinical Trials Group Study A5202. 19th Conference on Retroviruses and Opportunistic Infections (CROI), Seattle, WA, March 2012.
  10. Ribaudo H, Daar ES, Tierney C, Morse GD, Mollan K, Sax P, Fischl MA, Collier AC, Haas DW and ACTG 5202 Protocol Team. Premature Discontinuation of Atazanavir/Ritonavir (ATV/R) and UGT1A1 Variants in ACTG Protocol A5202. 19th Conference on Retroviruses and Opportunistic Infections (CROI), Seattle, WA, March 2012.
  11. Grady BJ, Ritchie MD, Acosta EP, Morse GD, Daar ES, Gulick RM, Robbins GK, McLaren P, Haas DW. Genome-Wide Association Study (GWAS) of Plasma Efavirenz Pharmacokinetics in AIDS Clinical Trials Group (ACTG) Protocols. 19th Conference on Retroviruses and Opportunistic Infections (CROI), Seattle, WA, March 2012.
  12. Reiss SN, Lombardo JC, Setlur S, Sayidine F, Govindaraju V, Felton CM, Morse GD. Application of Novel Handwriting Recognition Technology in an Oncology Specialty Pharmacy. 2nd Annual Association of Value-Based Cancer Care Meeting (AVBCC), Houston, TX, March 2012.
  13. Morse GD. Pharmacokinetic Considerations for Drug Interactions during HCV DAA Development. ACTG Scientific Retreat. Seattle, WA, March 2012.
  14. Reiss SN, Lombardo JC, Setlur S, Sayidine F, Govindaraju V, Felton CM, Morse GD. Application of Novel Handwriting Recognition Technology for Analyzing Prescription Orders in an Oncology Specialty Pharmacy – A Pilot Study. 24th Annual Meeting & Expo Academy of Managed Care Pharmacy (AMCP), San Francisco, CA, April 2012.
  15. Venuto CS, Ma Q, Difrancesco R, Hochreiter J, Morse GD. Comparison of Modeled and Non-modeled Clearance Values for Efavirenz. Translational Science 2012, Washington, D.C., April 2012.
  16. Gavi S, Sayidine F, Mudzviti T, Hakim J, Maponga CC, Difrancesco R, Morse GD. Novel Translational Approach to HIV Medication Management Utilizing Task Shifting and Healthcare Informatics. Translational Science 2012, Washington, D.C., April 2012.
  17. Martina C, Pearson T, Goodman S, Morse GD, Lewis V. Researcher Resilience Through Multidimensional Mentoring. Translational Science 2012, Washington D.C., April 2012.
  18. Difrancesco R, Tooley K, Taylor C, Morse GD. Using Quality-Driven Phased Assessments to Build Pharmacology Laboratory Capacity for HIV Clinical Research in Resource Limited Countries (RLC). 28th SQA Annual Meeting & Quality College, Miami, FL, April 2012.
  19. Gavi S, Sayidine F, Mudzviti T, Hakim J, Maponga CC, Difrancesco R, Morse GD. Novel Translational Approach to HIV Medication Management Utilizing Task Shifting and Healthcare Informatics – Social Enterprise Pitch. Unite For Sight 9th Annual Global Health & Innovation Conference at Yale University, New Haven, CT, April 2012.
  20. Guiastrennec B, Forrest A, Ma Q, Morse GD. Development of a Population Pharmacokinetic Model for Atazanavir in Drug Using Subjects. 2012 Virtual Poster Symposium ACCP. May 2012.
  21. Venuto C, Mollan K, Ma Q, Daar E, Sax P, Fischl MA, Collier A, Smith K, Tierney C, Morse GD, ACTG 5202 Protocol Team. Atazanavir Pharmacokinetics and Efficacy and Safety Outcomes by Sex in AIDS Clinical Trials Groups Study 5202 (A5202). ACTG Network Meeting, Washington D.C. July 2012.
  22. Morse GD. Drug Interactions and Challenges to Designing Combination HIV/HCV Protocols with new Directly Acting HCV Antivirals and Antiretrovirals. ACTG Network Meeting, Washington D.C. July 2012.
  23. Morse GD, Prasad P, Dube A. Nanomedicine and Translational Pharmacology: Considerations for HIV and TB. Division of Acquired Immunodeficiency Syndrome (DAIDS)/ National Institute of Allergy and Infectious Diseases (NAIDS)/ National Institute of Health(NIH) Meeting, Bethesda, Maryland. September 2012
  24. Reiss SN, Lombardo J, Sayidine F, Felton CM, Morse GD. Utilizing Health Information Technology to Perform Patient Safety Medication Reviews in a Patient Centered Medical Home Model for Oncology – A Pilot Study. American Society of Health System Pharmacists Midyear Meeting (ASHP). December 2012.
  25. Johnson DH, Venuto C, Daar ES, Morse GD, Sax P, Fischl MA, Collier AC, McLaren P, Ritchie M, Haas DW. Genome-wide Association Study of Atazanavir (ATV) Pharmacokinetics (PK) and Indirect Hyperbilirubinemia (HBR). Conference on Retroviruses and Opportunistic Infections(CROI). March 2013.
  26. Sulkowski M, Kang M, Matining R, Wyles D, Johnson V, Morse GD, Amorosa V, Bhattacharya D, Wong-Staal F, Glesby M. A Randomized, Double-blind, Phase 1b Study of the HCV Entry Inhibitor ITX 5061 in Treatment-naive, HCV monoinfected Adults: ACTG A5277. Conference on Retroviruses and Opportunistic Infections(CROI). March 2013.
  27. Mikula J, Hsiao CB, Sawyer JR, Ma Q, Morse GD. Comparative Effectiveness of Darunavir 1,200 mg Daily and Approved Dosing Strategies for Protease Inhibitor-Experienced Patients. International Association of Providers of AIDS Care (IAPAC). June 2013.

 

<<  Previous Page